Skip to content
LexBuild

Meeting of the Uniform Formulary Beneficiary Advisory Panel

---
identifier: "/us/fr/07-1059"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Meeting of the Uniform Formulary Beneficiary Advisory Panel"
title_number: 0
title_name: "Federal Register"
section_number: "07-1059"
section_name: "Meeting of the Uniform Formulary Beneficiary Advisory Panel"
positive_law: false
currency: "2007-03-07"
last_updated: "2007-03-07"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "07-1059"
document_type: "notice"
publication_date: "2007-03-07"
agencies:
  - "Defense Department"
  - null
fr_citation: "72 FR 10179"
fr_volume: 72
fr_action: "Notice of open meeting."
---

#  Meeting of the Uniform Formulary Beneficiary Advisory Panel

**AGENCY:**

Assistant Secretary of Defense (Health Affairs), Department of Defense.

**ACTION:**

Notice of open meeting.

**SUMMARY:**

This notice announces a meeting of the Uniform Formulary Beneficiary Advisory Panel. The panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary. The  meeting will be open to the public. Seating is limited and will be provided only to the first 220 people signing in. All persons must sign in legibly. Notice of this meeting is required under the Federal Advisory Committee Act.

**DATES:**

Wednesday, March 22, 2007, from 8 a.m. to 4 p.m.

**ADDRESSES:**

Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

**FOR FURTHER INFORMATION CONTACT:**

Major Travis Watson, TRICARE Management Activity, Pharmaceutical Operations Directorate, Beneficiary Advisory Panel, Suite 810, 5111 Leesburg Pike, Falls Church, VA 22041, telephone 703-681-2890, fax 703-681-1940, or e-mail at *[email protected].*

**SUPPLEMENTARY INFORMATION:**

The Uniform Formulary Beneficiary Advisory Panel will only review and comment on the development of the Uniform Formulary as reflected in the recommendations of the DOD Pharmacy and Therapeutics (P&T) Committee coming out of that body's meeting in February 2007. The P&T Committee information and subject matter concerning drug classes reviewed for that meeting are available at *http://pec.ha.osd.mil.* Any private citizen is permitted to file a written statement with the advisory panel. Statements must be submitted electronically to *[email protected]* no later than March 15, 2007. Any private citizen is permitted to speak at the Beneficiary Advisory Panel meeting, time permitting. One hour will be reserved for public comments, and speaking times will be assigned only to the first twelve citizens to sign up at the meeting, on a first-come, first-served basis. The amount of time allocated to a speaker will not exceed five minutes.

Dated: February 28, 2007.

C.R. Choate,

Alternate OSD Federal Register Liaison Officer, Department of Defense.